Dacarbazine combined targeted therapy versus dacarbazine alone in patients with malignant melanoma: a meta-analysis.
Dacarbazine combined targeted therapy versus dacarbazine alone in patients with malignant melanoma: a meta-analysis.
复制标题
Dacarbazine在恶性黑色素瘤患者中仅与Dacarbazine合并了靶向治疗：一项荟萃分析。
DOI：
10.1371/journal.pone.0111920
复制
发表时间：
2014
期刊：
影响因子：
3.7
通讯作者：
Zheng JN
中科院分区：
文献类型：
--
作者：
Jiang G;Li RH;Sun C;Liu YQ;Zheng JN
恶性黑色素瘤是最具侵略性和致命的皮肤癌形式。达卡巴嗪（DTIC）已被批准在常规临床实践中用于转移性黑色素瘤的一线治疗。然而，单药DTIC的应答率较低。本研究的目的是比较DTIC联合或不联合安慰剂和基于DTIC的联合治疗在晚期转移性黑色素瘤患者中的疗效和安全性。我们检索了2003年至2013年的电子数据库，如科克伦图书馆、MEDLINE、EBSCO、EMBASE、奥维德、CNKI和CBMDisc。主要结局指标为总体反应和1年生存率，次要结局指标为不良事件。9项随机对照试验（RCT）涉及2，481例患者，纳入荟萃分析。基于DTIC的联合治疗在总体缓解（联合风险比[RR]= 1.60，95%置信区间[CI]：1.27-2.01）和1年生存率（联合RR = 1.26，95% CI：1.14-1.39）方面上级DTIC单药治疗。 与DTIC单药治疗组相比，接受DTIC联合治疗的患者不良事件发生率更高，包括恶心（合并RR = 1.23，95% CI：1.10-1.36）、呕吐（合并RR = 1.73，95% CI：1.41-2.12）和中性粒细胞减少（合并RR = 1.75，95% CI：1.42-2.16）。 这些数据表明，DTIC为基础的联合治疗可以适度提高总体反应和1年生存率，但增加了不良事件的发生率。需要进一步的大规模、高质量、安慰剂对照、双盲试验来证实这一结论。
Malignant melanoma is the most aggressive and deadly form of skin cancer. Dacarbazine (DTIC) has been the approved first-line treatment for metastatic melanoma in routine clinical practice. However, response rates with single-agent DTIC are low. The objective of this study was to compare the efficacy and safety of DTIC with or without placebo and DTIC-based combination therapies in patients with advanced metastatic melanoma. We searched from electronic databases such as The Cochrane Library, MEDLINE, EBSCO, EMBASE, Ovid, CNKI, and CBMDisc from 2003 to 2013. The primary outcome measures were overall response and 1-year survival, and the secondary outcome measurements were adverse events. Nine randomized controlled trials (RCTs) involving 2,481 patients were included in the meta-analysis. DTIC-based combination therapies was superior to DTIC alone in overall response (combined risk ratio [RR] = 1.60, 95% confidence interval [CI]: 1.27–2.01) and 1-year survival (combined RR = 1.26, 95% CI: 1.14–1.39). Patients with DTIC-based combination therapies had higher incidence of adverse events including nausea (combined RR = 1.23, 95% CI: 1.10–1.36), vomiting (combined RR = 1.73, 95% CI: 1.41–2.12) and neutropenia (combined RR = 1.75, 95% CI: 1.42–2.16) compared to the group for DTIC alone. These data suggested that DTIC-based combination therapies could moderately improve the overall response and the 1-year survival but increased the incidence of adverse events. Further large-scale, high-quality, placebo-controlled, double-blind trials are needed to confirm this conclusion.
登录
查看更多内容
影响因子：
15.8
作者：
Moher D;Liberati A;Tetzlaff J;Altman DG;PRISMA Group
通讯作者：
PRISMA Group
影响因子：
51.1
作者：
Robert, Caroline;Dummer, Reinhard;Middleton, Mark R.
通讯作者：
Middleton, Mark R.
DOI：
10.1158/1078-0432.ccr-11-0556
发表时间：
2011-09-01
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Querfeld C;Rosen ST;Guitart J;Rademaker A;Pezen DS;Dolan ME;Baron J;Yarosh DB;Foss F;Kuzel TM
通讯作者：
Kuzel TM
影响因子：
45.3
作者：
Bedikian, Agop Y.;Millward, Michael;Haluska, Frank G.
通讯作者：
Haluska, Frank G.
影响因子：
254.7
作者：
Jemal, Ahmedin;Siegel, Rebecca;Ward, Elizabeth
通讯作者：
Ward, Elizabeth